Tuberculosis, spinal

Summary

Tuberculosis, spinal (MONDO:0043836) is a disease and 6 clinical trials. Top therapeutic interventions include ethambutol, isoniazid, and pyrazinamide. A subtype of vertebral column disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	tuberculosis, spinal
Mondo ID	MONDO:0043836
MeSH	D014399
NCIT	C35087
SNOMED CT	35984006
UMLS	C0041330
MedGen	11948
GARD	0025869
Anatomy (UBERON)	UBERON:0001130
Is cancer (heuristic)	no

Also known as: disease, pott · disease, pott’s · pott disease · pott’s disease · pott’s paraplegia · Potts disease · spinal Tuberculoses · spinal tuberculosis · Tuberculoses, spinal · tuberculosis of vertebral column

Disease family

This is a subtype of vertebral column disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › skeletal system disorder › vertebral column disorder › tuberculosis, spinal

Related subtypes (14): spondylocostal dysostosis, sacrum chordoma, epidural spinal canal neoplasm, Baastrup syndrome, lumbosacral lipoma, spinal stenosis, intervertebral disk degenerative disorder, coccygodynia, vertebral joint disorder, sacrococcygeal teratoma, spinal cord injury, vertebral disorder, lumbar disk disease, dropped head syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE2	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02477852	PHASE4	UNKNOWN	The Optimal Duration of Preoperative Anti-tuberculosis Treatment of Spinal Tuberculosis
NCT06917495	PHASE2	NOT_YET_RECRUITING	Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis
NCT04493918	PHASE2	UNKNOWN	Effectivity of Mesenchymal Stem Cell on Vertebral Bone Defect Due to Mycobaterium Tuberculosis Infection
NCT05610098	Not specified	RECRUITING	Gene Expression Profiles in Spinal Tuberculosis.
NCT02638272	Not specified	COMPLETED	Early Outcomes of Radical Debridement Versus no Debridement Under Different Surgical Procedures
NCT02971644	Not specified	UNKNOWN	Cobalt Alloy Pedicle Screw Implantation for Severe Kyphosis Deformity in Spinal Tuberculosis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ETHAMBUTOL	4	2
ISONIAZID	4	2
PYRAZINAMIDE	4	2
RIFAMPIN	4	2
RIFAPENTINE	4	1
CHEMBL1340583	0	1